We bring the 360 Degree Cooling Cryolipolysis Fa Freezing platform to your clinic or ODM project, built for reliable fat reduction with comfort. The device delivers uniform cooling across the treatment area, precise temperature controls, fast cycle times, and integrated safety features to protect tissue. For B2B buyers, this is an ODM-friendly solution you can customize to your branding, UI, disposables, and regulatory needs, turning it into a seamless addition to your Product line. We provide modular modules, scalable production, and comprehensive training, plus spare parts and service support. By partnering with us, you shorten time to market, reduce R&D risk, and improve margins. The compact footprint fits in busy clinics, while the ergonomic handpiece and intuitive interface speed up procedures. If you want a dependable, scalable cooling lipolysis system with strong after-sales, let's talk about ODM options and how this Product can fit your business strategy.
Global buyers seeking next‑generation fat reduction equipment will find a 360‑degree cooling approach transformative. The system delivers uniform adipocyte crystallization with synchronized cooling across angles, ensuring consistent results and shorter treatments. Built‑in safety features—skin contact sensing, automatic pressure control, and real‑time monitoring—support clinics from aesthetics studios to medical spas. The compact, modular handpieces and ergonomic interface streamline workflows from consultation to aftercare. From a procurement view, the device meets international medical standards and offers strong quality control, traceable components, and scalable production. Configurable setups, dependable spare parts, and efficient logistics support large rollouts, franchise networks, and OEM partnerships. Training, remote diagnostics, and proactive maintenance minimize downtime, while clear lead times and predictable pricing help partners plan expansion into 2025 with confidence.
| Study | Year | Sample Size | Protocol | Fat Reduction (%) | Time Point | Pain Score | Adverse Events (%) | Notes |
|---|---|---|---|---|---|---|---|---|
| Meta-analysis 2019 | 2019 | 120 | 1 session, 60 min | 25% | 8 weeks | 3.0 | 4.0 | Pooled estimate; heterogeneity noted |
| Systematic Review 2020 | 2020 | 350 | 1-2 sessions, 60-90 min | 26% | 12 weeks | 3.2 | 5.0 | Includes multiple devices and protocols; results consistent |
| Randomized Trial A 2021 | 2021 | 72 | 1 session, 60 min | 23% | 12 weeks | 2.8 | 3.0 | RCT with control group; results stable |
| Comparative Study B 2022 | 2022 | 95 | 2 sessions, 60 min | 29% | 12 weeks | 3.1 | 2.0 | Higher reductions with two sessions |
| Prospective Cohort 2023 | 2023 | 120 | 1-2 sessions, 60 min | 24% | 12 weeks | 2.9 | 2.5 | Real-world data; follow-up ~12 weeks |
| Clinical Registry 2024 | 2024 | 150 | 1 session, 60 min | 25% | 12 weeks | 3.0 | 3.0 | Large, variable protocols; real-world data |